Abstract
Reversible phosphorylation of proteins, principally on serine, threonine, or tyrosine residues, is central to the regulation of most aspects of eukaryotic cell function. Dysregulation of protein kinases and protein phosphatases is linked to numerous human diseases. Consequently, many efforts have been made to target these enzymes with small molecules in order to develop new therapeutic agents. While protein kinase inhibitors have been successfully brought to the market, the development of specific protein phosphatase inhibitors is still in its infancy. The largest and most diverse protein phosphatase superfamily in humans is comprised by the protein tyrosine phosphatases, a group of over 100 enzymes. Here, we describe high-throughput screening methods to search for protein tyrosine phosphatase activity modulators. We illustrate the implementation of relatively simple phosphatase assays, using generic absorbance- or fluorescence-based substrates, in 384- or 1536-well microtiter plates. We discuss steps to optimize HTS assay quality and performance, and describe several PTP screening methods on the basis of previously performed successful HTS campaigns. Finally, we discuss how to confirm, follow up, and prioritize hit compounds, and point out a number of common pitfalls that are encountered in this process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hunter T, Sefton BM (1980) Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci U S A 77:1311–1315
Hunter T (1998) The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect 94:81–119
Hunter T (2000) Signaling–2000 and beyond. Cell 100:113–127
Larsen M, Tremblay ML, Yamada KM (2003) Phosphatases in cell-matrix adhesion and migration. Nat Rev Mol Cell Biol 4:700–711
Alonso A, Sasin J, Bottini N et al (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699–711
Mustelin T, Vang T, Bottini N (2005) Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 5:43–57
Halle M, Tremblay ML, Meng TC (2007) Protein tyrosine phosphatases: emerging regulators of apoptosis. Cell Cycle 6:2773–2781
Pao LI, Badour K, Siminovitch KA et al (2007) Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol 25:473–523
Hunter T (2009) Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 21:140–146
Rhee I, Veillette A (2012) Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol 13:439–447
Cohen P (2002) Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309–315
Tautz L, Pellecchia M, Mustelin T (2006) Targeting the PTPome in human disease. Expert Opin Ther Targets 10:157–177
Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7:833–846
Vang T, Miletic AV, Arimura Y et al (2008) Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 26:29–55
Julien SG, Dube N, Hardy S et al (2011) Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11:35–49
Bialy L, Waldmann H (2005) Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew Chem Int Ed Engl 44:3814–3839
Vintonyak VV, Antonchick AP, Rauh D et al (2009) The therapeutic potential of phosphatase inhibitors. Curr Opin Chem Biol 13:272–283
Barr AJ (2010) Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem 2:1563–1576
Sobhia ME, Paul S, Shinde R et al (2012) Protein tyrosine phosphatase inhibitors: a patent review (2002–2011). Expert Opin Ther Pat 22:125–153
He R, Zeng LF, He Y et al (2013) Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 280:731–750
Mayr LM, Bojanic D (2009) Novel trends in high-throughput screening. Curr Opin Pharmacol 9:580–588
Kool J, Lingeman H, Niessen W et al (2010) High throughput screening methodologies classified for major drug target classes according to target signaling pathways. Comb Chem High Throughput Screen 13:548–561
Tautz L, Mustelin T (2007) Strategies for developing protein tyrosine phosphatase inhibitors. Methods 42:250–260
Montalibet J, Skorey KI, Kennedy BP (2005) Protein tyrosine phosphatase: enzymatic assays. Methods 35:2–8
Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73
Feng BY, Shoichet BK (2006) A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc 1:550–553
Sergienko E, Xu J, Liu WH et al (2012) Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation. ACS Chem Biol 7:367–377
Bobkova EV, Liu WH, Colayco S et al (2011) Inhibition of the hematopoietic protein tyrosine phosphatase by phenoxyacetic acids. ACS Med Chem Lett 2:113–118
Goebel-Goody SM, Baum M, Paspalas CD et al (2012) Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev 64:65–87
Vang T, Congia M, Macis MD et al (2005) Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37:1317–1319
Xie Y, Liu Y, Gong G et al (2008) Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase. Bioorg Med Chem Lett 18:2840–2844
Vang T, Liu WH, Delacroix L et al (2012) LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 8:437–446
Freyer MW, Lewis EA (2008) Isothermal titration calorimetry: experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. Methods Cell Biol 84:79–113
Cummings MD, Farnum MA, Nelen MI (2006) Universal screening methods and applications of ThermoFluor. J Biomol Screen 11:854–863
Bova MP, Mattson MN, Vasile S et al (2004) The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide. Arch Biochem Biophys 429:30–41
Johnston PA, Foster CA, Tierno MB et al (2009) Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol 7:250–265
Tautz L, Bruckner S, Sareth S et al (2005) Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J Biol Chem 280:9400–9408
Acknowledgments
This work was supported by NIH Roadmap Initiative grants U54HG003916 and U54HG005033 (to CPCCG), and NIH grants R03MH095532, R03MH084230, and R21CA132121 (to L.T.).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Tautz, L., Sergienko, E.A. (2013). High-Throughput Screening for Protein Tyrosine Phosphatase Activity Modulators. In: Millán, J. (eds) Phosphatase Modulators. Methods in Molecular Biology, vol 1053. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-562-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-62703-562-0_14
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-561-3
Online ISBN: 978-1-62703-562-0
eBook Packages: Springer Protocols